Latest Breaking News On - Media france - Page 8 : comparemela.com
(0) POXEL SA (Euronext POXEL FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH) today announced the publication of the meeting notice for the Annual General Meeting, which will take place in a closed virtual session on June 23
rd, 2021 at 1.00pm CEST.
In the context of the COVID-19 pandemic and in accordance with the regulations introduced to limit or prohibit travel and collective gatherings to prevent the spread of the COVID-19 virus (article 4 of Order n° 2020-321 of March 25, 2020 as amended and extended and decree n° 2020-1310 of October 29, 2020 as amended and extended including by the decree n° 2021-541 of May 1, 2021), Poxel s Board of Directors has decided to hold the 2021 Annual General Meeting behind closed doors, without the physical presence of shareholders. Therefore, the Company strongly encourages its shareholders to use th
Japan
China
Boston
Massachusetts
United-states
Taiwan
Tokyo
South-korea
France
French
Japanese
Sumitomo-dainippon-pharma
Poxel SA: Poxel Announces Participation at Upcoming Virtual Investor Conferences in June POXEL SA (Euronext POXEL FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced its participation at upcoming virtual investor conferences in June 2021. Thomas Kuhn, CEO, will present the company and Poxel management team members will be available for one-on-one virtual meetings.
Jefferies Global Healthcare Conference
st from 11:00 am to 11:25 am ET.
JMP Securities Conference
th from 10:30 am to 10:55 am ET.
Raymond James Human Health Innovations Conference
Date: June 21-23
nd from 8:40 am to 9:10 am ET.
Japan
China
Boston
Massachusetts
United-states
Taiwan
Tokyo
South-korea
France
Japanese
Sumitomo-dainippon-pharma
Arthur-rouill